Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 30 member 9 (SLC30A9) is a **mitochondrial zinc transporter** that exports Zn2+ from mitochondria to the cytosol, helping maintain intracellular zinc homeostasis and ensuring normal mitochondrial morphology and function[1][2][3][5][7]. SLC30A9 is localized to the mitochondrial membrane and operates as a proton-coupled zinc antiporter, utilizing the mitochondrial proton gradient to export zinc ions. Loss of SLC30A9 results in mitochondrial zinc overload, swelling, impaired mitochondrial metabolism, and is associated with neurodegenerative and developmental disorders, such as Birk-Landau-Perez syndrome. In addition to its main transporter function, SLC30A9 has minor roles as a nuclear receptor coactivator and may influence Wnt-responsive gene transcription. SLC30A9 is evolutionarily conserved and essential for organismal health[1][2][4][5][7].
Drugs targeting this molecule would likely act as **inhibitors or agonists** of mitochondrial zinc export activity, altering intracellular/mitochondrial zinc distribution; however, no approved or experimental drugs are specifically referenced in current literature[2][1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 30 member 9 (SLC30A9).